ELDN
ELEDON PHARMA (ELDN)
NASDAQ
$3.44-$0.05 (-1.40%)
Price as of Jun 03, 2026 7:58 PM EDT
  • $294.1M
    Market Cap
  • 15.18%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-66.3M
+27.52%
-52.0M
+71.43%
-30.3M
+11.94%
-27.1M
+14.09%
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
83.3M
+17.96%
70.6M
+64.13%
43.0M
-51.37%
88.4M
+139.86%
Operating Profit
-45.6M
+27.49%
-35.8M
-69.32%
-116.5M
+31.79%
-88.4M
+139.86%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
4.2M
+7.54%
3.9M
+46.75%
2.7M
+478.79%
462,000
+6,500.00%
Income before Taxes
-45.6M
+27.49%
-35.8M
-69.32%
-116.5M
+32.48%
-88.0M
+138.65%
Income Taxes
35,000
-91.88%
431,000
N/A
0
N/A
0
+100.00%
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-45.6M
+26.07%
-36.2M
-68.95%
-116.5M
+32.48%
-88.0M
+154.93%
Net Income from Continuing Operations Applicable to Common
-45.6M
+27.49%
-35.8M
-69.32%
-116.5M
+32.48%
-88.0M
+138.65%
Basic EPS and Net Income
-0.52
-21.21%
-0.66
-86.05%
-4.73
-23.21%
-6.16
+164.38%
Diluted EPS and Net Income
-0.52
-21.21%
-0.66
-86.05%
-4.73
-23.21%
-6.16
+164.38%
Basic Weighted Average Shares
81.8M
+68.58%
48.5M
+97.18%
24.6M
+72.34%
14.3M
-3.61%
Diluted Weighted Average Shares
81.8M
+68.58%
48.5M
+97.18%
24.6M
+72.34%
14.3M
-3.61%
Balance Sheet
Cash and Cash Equivalents
22.8M
+10.99%
20.5M
+345.56%
4.6M
-91.82%
56.4M
-33.51%
Short-Term Investments
110.5M
-7.61%
119.6M
+157.32%
46.5M
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
133.3M
-4.88%
140.2M
+174.31%
51.1M
-9.41%
56.4M
-33.51%
Total Current Assets
135.7M
-5.60%
143.7M
+156.07%
56.1M
-5.69%
59.5M
-32.63%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
322,000
-11.29%
363,000
+95.16%
186,000
+24.00%
150,000
-62.50%
Total Assets
169.0M
-4.73%
177.4M
+99.18%
89.1M
-4.02%
92.8M
-45.59%
Income Taxes Payable
2.2M
+0.18%
2.2M
+24.60%
1.8M
0.00%
1.8M
0.00%
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
18.3M
+58.45%
11.6M
+197.23%
3.9M
-39.85%
6.5M
+47.13%
Total Long-Term Debt
0
N/A
0
N/A
0
N/A
0
N/A
Total Long-Term Liabilities
16.1M
-67.77%
49.9M
-37.44%
79.7M
+1,950.81%
3.9M
-0.44%
Total Liabilities
32.2M
-45.62%
59.3M
-27.60%
81.9M
+850.73%
8.6M
+31.39%
Retained Earnings
-401.2M
+12.83%
-355.6M
+11.33%
-319.4M
+57.45%
-202.9M
+76.56%
Total Stockholders Equity
81.1M
+29.85%
62.4M
+766.34%
7.2M
-91.44%
84.2M
-48.67%
Total Shares Outstanding
75.4M
+26.16%
59.8M
+146.93%
24.2M
+75.75%
13.8M
-3.70%
Cash Flow
Cash from Operating Activities
-62.3M
+31.88%
-47.3M
+19.59%
-39.5M
+39.06%
-28.4M
-1.69%
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
10.8M
+115.35%
-70.3M
+55.26%
-45.3M
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
53.8M
-59.70%
133.5M
+304.40%
33.0M
+7,453.45%
-449,000
0.00%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-26.34%
-3.02%
-27.16%
-78.81%
-128.16%
+91.84%
-66.81%
+255.99%
Return on Equity
-63.56%
-38.82%
-103.90%
-59.26%
-255.03%
+259.76%
-70.89%
+264.24%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
7.40
-40.42%
12.42
-13.85%
14.41
+56.77%
9.19
-54.21%
Cash Ratio
1.24
-29.95%
1.78
+49.90%
1.18
-86.41%
8.71
-54.80%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow